O1918 

O1918 is a selective non-CB₁ receptor and GPR18 antagonist.

non-CB₁ vascular cannabinoid receptor^[1], GPR18^[2].

Decreases in HR, blood pressure, MBF and RBF by about 20 beats/min, 5-10 mmHg and 0.7 and 0.2 mL/min, respectively, are observed after injection of O1918 (3 µmol/kg). O1918 causes an inhibition of the anandamide-stimulated decreases in MBP, SBP and DBP by 55, 38 and 42% respectively. Similarly, this antagonist reduces the methanandamide-stimulated fall in SBP and DBP by 44 and 32%, respectively, and tends to diminish the decrease in MBP by 28%. O1918 also diminishes the fall in MBF and RBF induced by anandamide by 61 and 67% and that induced by methanandamide by 74 and 49% respectively. Cannabidiol does not affect basal cardiovascular parameters whereas O1918 decreases HR by about 15 beats/min and SBP, DBP and MBP by about 15 mmHg. In pithed rats anandamide (3 µmol/kg) causes only an increase in MBF and RBF. The anandamide-induced long-lasting fall in MBP, SBP and DBP is reduced by cannabidiol by 40-46% and by O-1918 by 55, 64 and 35, respectively^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

286.41

C₁₉H₂₆O₂

536697-79-7

液体

Colorless to light yellow

Room temperature in continental US; may vary elsewhere.

Solution, -20°C, 2 years

• [1]. Agnieszka Zakrzeska, et al. A cannabinoid receptor, sensitive to O-1918, is involved in the delayed hypotension induced by anandamide in anaesthetized rats. Br J Pharmacol. 2010 Jun; 160(3): 574–584.  [Content Brief]

  [2]. Matouk AI, et al. Abnormal cannabidiol confers cardioprotection in diabetic rats independent of glycemic control. Eur J Pharmacol. 2018 Feb 5;820:256-264.  [Content Brief]